Biontech estimates that its coronavirus vaccine will also be effective against emerging strains of the virus, but is preparing for a third vaccine or adaptation to a new mutant strain.
The company also estimates that a third vaccination could be of great value, as the immunity of the existing one decreases over time.
Mainz-based Biontech and US-based Pfizer, with which it works, plan to “produce three billion doses of coronavirus vaccine this year.
This number will increase again next year.
“Biontech wants to produce at least 50% of the planned doses of the vaccine itself,” said the CEO of the German company.